-
Je něco špatně v tomto záznamu ?
Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells
M. Jakubíková, J. Piťha, H. Marečková, M. Týblová, I. Nováková, J. Schutzner,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antigeny CD4 MeSH
- dospělí MeSH
- hodnocení výsledků zdravotní péče * MeSH
- hormony kůry nadledvin terapeutické užití MeSH
- imunosupresiva terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- myasthenia gravis krev farmakoterapie chirurgie MeSH
- následné studie MeSH
- počet CD4 lymfocytů MeSH
- počet lymfocytů MeSH
- receptor interleukinu-2 - alfa-podjednotka MeSH
- regulační T-lymfocyty * MeSH
- thymektomie metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Myasthenia gravis (MG) is the autoimmune disorder in which the thymus is considered the pathogenic organ. Thymectomy (TE) is a therapeutic option for MG and often ameliorates clinical symptoms. METHODS: We evaluated clinical features and outcomes after TE in patients without thymoma and the influence of TE with or without concomitant immunotherapy on the CD4(+)CD25(+) regulatory T cell subpopulation of lymphocytes in peripheral blood in defined followed groups of nonthymomatous MG patients. RESULTS: A total of 46 patients with generalized MG who underwent transsternal TE were identified. Neurologic outcomes after TE were favorable for the majority of patients mainly from the group treated with corticosteroids or combined immunosuppressive treatment. TEs with immunosuppressive treatment in MG patients were associated with increased percentages of CD4(+)CD25(+) cells (p<0.001). No significant change in the postoperative levels of CD4(+)CD25(+) cells was observed in thymectomized patients who preoperatively only received pyridostigmine. Also their clinical response to TE after 2 years of follow-up was worst of all followed groups. CONCLUSIONS: The exact mechanism by which TE ameliorates symptoms of MG is yet not clear. These observations indicate that increased percentages of CD4(+)CD25(+) T cells in MG may be related to disease stability and that TE and synergistic effect with concomitant, continuing immunotherapy augmented the proportion of CD4(+)CD25(+) T cells. On the basis of our observations TE alone is not enough to increase the number of circulating CD4(+)CD25(+) regulatory T cells and to establish complete stable remission.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028268
- 003
- CZ-PrNML
- 005
- 20161025111037.0
- 007
- ta
- 008
- 161005s2015 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jns.2015.08.029 $2 doi
- 024 7_
- $a 10.1016/j.jns.2015.08.029 $2 doi
- 035 __
- $a (PubMed)26320610
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Jakubíková, Michala $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic. Electronic address: michala.jakubikova@vfn.cz.
- 245 10
- $a Two-year outcome of thymectomy with or without immunosuppressive treatment in nonthymomatous myasthenia gravis and its effect on regulatory T cells / $c M. Jakubíková, J. Piťha, H. Marečková, M. Týblová, I. Nováková, J. Schutzner,
- 520 9_
- $a BACKGROUND: Myasthenia gravis (MG) is the autoimmune disorder in which the thymus is considered the pathogenic organ. Thymectomy (TE) is a therapeutic option for MG and often ameliorates clinical symptoms. METHODS: We evaluated clinical features and outcomes after TE in patients without thymoma and the influence of TE with or without concomitant immunotherapy on the CD4(+)CD25(+) regulatory T cell subpopulation of lymphocytes in peripheral blood in defined followed groups of nonthymomatous MG patients. RESULTS: A total of 46 patients with generalized MG who underwent transsternal TE were identified. Neurologic outcomes after TE were favorable for the majority of patients mainly from the group treated with corticosteroids or combined immunosuppressive treatment. TEs with immunosuppressive treatment in MG patients were associated with increased percentages of CD4(+)CD25(+) cells (p<0.001). No significant change in the postoperative levels of CD4(+)CD25(+) cells was observed in thymectomized patients who preoperatively only received pyridostigmine. Also their clinical response to TE after 2 years of follow-up was worst of all followed groups. CONCLUSIONS: The exact mechanism by which TE ameliorates symptoms of MG is yet not clear. These observations indicate that increased percentages of CD4(+)CD25(+) T cells in MG may be related to disease stability and that TE and synergistic effect with concomitant, continuing immunotherapy augmented the proportion of CD4(+)CD25(+) T cells. On the basis of our observations TE alone is not enough to increase the number of circulating CD4(+)CD25(+) regulatory T cells and to establish complete stable remission.
- 650 _2
- $a hormony kůry nadledvin $x terapeutické užití $7 D000305
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antigeny CD4 $7 D015704
- 650 _2
- $a počet CD4 lymfocytů $7 D018791
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a receptor interleukinu-2 - alfa-podjednotka $7 D053645
- 650 _2
- $a počet lymfocytů $7 D018655
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a myasthenia gravis $x krev $x farmakoterapie $x chirurgie $7 D009157
- 650 12
- $a hodnocení výsledků zdravotní péče $7 D017063
- 650 12
- $a regulační T-lymfocyty $7 D050378
- 650 _2
- $a thymektomie $x metody $7 D013934
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Piťha, Jiří $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
- 700 1_
- $a Marečková, Helena $u Department of Immunology and Microbiology, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
- 700 1_
- $a Týblová, Michaela $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
- 700 1_
- $a Nováková, Iveta $u Department of Neurology and Clinical Neuroscience Center, 1st Faculty of Medicine of Charles University and General Teaching Hospital in Prague, Czech Republic.
- 700 1_
- $a Schutzner, Jan $u Third Department of Surgery, 1st Faculty of Medicine of Charles University and University Hospital Motol, Czech Republic.
- 773 0_
- $w MED00003004 $t Journal of the neurological sciences $x 1878-5883 $g Roč. 358, č. 1-2 (2015), s. 101-6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26320610 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161025111451 $b ABA008
- 999 __
- $a ok $b bmc $g 1166582 $s 952898
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 358 $c 1-2 $d 101-6 $e 20150820 $i 1878-5883 $m Journal of the neurological sciences $n J Neurol Sci $x MED00003004
- LZP __
- $a Pubmed-20161005